We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Aridis Receives FDA Fast Track Designation for Aerucin™

News   Jul 02, 2015

 
Aridis Receives FDA Fast Track Designation for Aerucin™
 
 
 

RELATED ARTICLES

Trial Suggests Immunotherapy Is Superior to Chemotherapy in Some Children With Relapsed Leukemia

News

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

READ MORE

A Prescription of Short-term Exercise Could Help Reduce the Side-effects of Prostate Hormone Therapy

News

A prescription of short-term exercise for patients with advanced prostate cancer could help to reduce the side-effects of hormone therapy, according to new research from the University of East Anglia.

READ MORE

Ribosome-based Treatments: A Sought After Therapy Option for Orphan Diseases?

News

Recently, Urania Therapeutics announced that it has successfully raised €3.53M ($3.89M) in seed funding to unlock the therapeutic potential of ribosome-based treatments. We spoke with Jean-Paul Renaud, President and CSO of Urania Therapeutics, to learn more about the mechanisms of readthrough compounds and how the company hopes to provide treatment solutions for orphan diseases.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE